MPR Weekly Dose 199 — Fasenra Expanded Approval; HIV Tx Approval Expanded; ALS Drug Discontinued; CRL for Apomorphine Device; At-Home Mpox Test

Asthma treatment gains approval for severe cases in pediatrics; Dovato gains expanded indication; Decision taken to remove ALS drug from market; Complete Response Letter issued for apomorphine device; At-home Mpox test kit made available.

Episode metadata supplied by the publisher feed · Published Apr 12, 2024

Embed this episode

Attribution link and audio player

Ready to play

MPR Weekly Dose 199 — Fasenra Expanded Approval; HIV Tx Approval Expanded; ALS Drug Discontinued; CRL for Apomorphine Device; At-Home Mpox Test

0:00 11:25

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 11 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on April 12, 2024.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!